Dr. Andrew Sledziewski – Founder & CEO
Biotechnology executive with more than 25 years of professional experience in all aspects of discovery and preclinical development of protein pharmaceuticals, molecular diagnostics, novel biomedical technology management, and formation of start-up biotech organizations.
Directed research and development activities for multiple biotechnology companies and directly participated in securing financing for their activities. At Epigenomics (2000-2011) as Senior Vice President of Research supervised research and intellectual property activities, managed multimillion-dollar external contracts, and co-invented EpiproColon, a Septin9 blood-based product for early detection of colorectal cancer. At ZymoGenetics (1985-1998) Senior Vice President – Protein Discovery planned, budgeted, and executed all discovery and pre-clinical development of biopharmaceuticals; supervised R&D staff of more than 90 scientists with an approximate budget of $20M. Author (over 20 peer-reviewed publications) and inventor (17 US granted patents). At GCE, co-inventor of the Company’s technology and business concept.

Dr. Theo deVos Co-Founder CSO
Biotech executive with 25+ years experience in international companies focused on molecular diagnostics and biotechnology, most recently as Co-Managing Director of Ares Genetics, a Vienna-based company developing DNA-based infectious disease services and solutions for drug response prediction. He participated in a number of startups as a bench scientist, research director and CSO, where he was responsible for setting the course, delivering on R&D objectives, managing project teams and managing clinical and scientific advisors and advisory boards. In the course of product development and commercialization, he participated in US FDA submissions and had direct responsibility for product development, quality systems and manufacturing. As part of the product approval process, he was responsible for the design and deployment of multiple clinical trials to support regulatory filings. Commercialization depended on establishing business relationships, either for the clinical service or product offered. To that end, he has participated in, and driven business development efforts to establish partnerships and contracts for molecular diagnostic products.
Through extensive experience across the full range of MDx product development and commercialization, his strengths are in strategic planning, and developing and implementing both R&D and commercial operations.

Dr. Jan Bacher, Dipl. Ing. COO
Electrical engineer and biotechnology veteran with 25+ years in the medical device and in-vitro diagnostics (IVD) industry with a proven track record of driving novel technologies and concepts from inception to commercial products. He has demonstrated the successful application of a wide range of technical specialties (in-vivo and in-vitro sensor and detection technologies, mechatronics, electronics hardware, firmware and software, data science, and data mining) as well as the setup and operation of a highly automated 17, 000 sq ft cleanroom production facility for IVD cartridges and was responsible for global multicenter clinical trials and product approvals in a tightly regulated industry. R&D and operations manager with many years of experience working with cross-functional teams small and large in an international setting. Co-founder of German molecular diagnostics company Curetis AG in 2007, where he was Managing Director / Chief Operating Officer from 2008 until Sep. 2024. He was instrumental in driving the company from a 6 person VC financed startup into a commercial-stage, publicly listed IVD company with 130+ staff in 7 countries, manufacturing and selling its products in over 40 countries worldwide, including the U.S., EMEA, China, Apac and LatAm.